Spotlight Stories
-
Making The Right Deal For Biohaven
3/1/2023
Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.
-
Translating Nobel Prize Winning Science Into Medicine
3/1/2023
2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.
-
Scientist-Founders Reshape The Bio Biz
2/1/2023
Recently, it seems, new scientist-leaders have emerged whose backgrounds and acquired knowledge begin in science but grow to encompass business as well. Mammoth Biosciences is building, and betting, on such a model.
-
With Fundraising, A Track Record Matters: GeoVax’s David Dodd
2/1/2023
Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.
-
Why Takeda Is Focusing So Much On Plasma-Derived Therapies
2/1/2023
Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.
-
Verve Therapeutics: How To Build A Gene Editing Biotech
1/3/2023
Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.
-
Peter Marks: Prioritizing Better Communication And Faster Product Reviews
1/3/2023
In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.
-
Executive Outlook: Crafting New Solutions For Persisting Problems
12/1/2022
Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).
-
Will The Finance And Funding Pendulum Swing Back To Black In 2023?
12/1/2022
Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.
-
Biopharma Public Opinion, Pricing, Politics
12/1/2022
Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.